Company: NIVFW
Filing Date: 2025-05-20
Form Type: F-1/A
Source: 0001213900-25-045737
Chunk: 138

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-20
Form: F-1/A
Chunk 138
---
 (the “Managing Members”). The Managing Members, in their capacity as Managing Members of the Adviser, may also be deemed to have investment discretion and voting power over the shares of common stock beneficially owned by the Selling Securityholder. The Fund, the Adviser and the Managing Members each disclaim any beneficial ownership of such holdings. The address of this Selling Securityholder is c/o ATW Partners Opportunities Management, LLC, 1 Pennsylvania Plaza, Suite 4810, New York, NY 10119. |

| (4) | The business address of White Lion is 17631 Ventura Blvd, Suite 1008, Encino, CA 91316                                                        |
| (5) | The business address of Genetics & IVF Institute, Inc. is 3015 Williams Drive, Fairfax VA 22031, USA                                          |
| (6) | The business address of A SPAC (Holdings) Limited is Ritter House, Wickhams Cay, II, PO Box 3170,                                             
 Road Town, Tortola VG1110, British Virgin Islands.                                                                                            |
| (7) | This                                                                                                                                          
 column lists the number of our ordinary shares beneficially owned by this Selling Securityholder as of May 16, 2025 after giving effect       
 to the Maximum Percentage (as defined in the paragraph above). Without regard to the Maximum Percentage, as of May 16, 2025, this Selling     
 Shareholder would beneficially own an aggregate of 14,687,027 of our Ordinary Shares (of which 12,000,000 shares are being registered         
 for resale under this prospectus), consisting of (i) 2,682,344 shares underlying the Fourth Tranche Note held by this Selling Securityholder, 
 convertible at an alternate conversion price of $0.2388, (ii) 10,537,780 shares underlying the Additional Remaining Notes to be acquired      
 by this Selling Securityholder, convertible at an alternate conversion price of $0.2388, (iii) 1,132,869 shares underlying the Series         
 A Warrants held by this Selling Securityholder, currently exercisable at an exercise price of $0.9203, (iv) 7,425 shares underlying the       
 Series B Warrants held by this Selling Securityholder, the exercise price of the Series B Warrants was prepaid, except for a nominal          
 exercise price of $0.001 per share, and (v) 326,609 shares underlying the Exchange Warrants held by this Selling